Clarus Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03973840
- Locations
- 🇺🇸
Clarus Therapeutics, Inc, Northbrook, Illinois, United States
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02921386
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
- Conditions
- Hypogonadism
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT02722278
- Locations
- 🇺🇸
Multiple Sites in the United States, Northbrook, Illinois, United States
Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men
- Conditions
- Hypogonadism
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02697188
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, California, United States
🇺🇸dgd Research, Inc, San Antonio, Texas, United States
Phlebotomy Study of Testosterone Undecanoate
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02670343
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States
Safety and Efficacy Trial of Testosterone Undecanoate
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT01765179
- Locations
- 🇺🇸
Medical Affliated Research Center, Inc., Huntsville, Alabama, United States
🇺🇸SC Clinical Research, Inc., Garden Grove, California, United States
🇺🇸South ORange County Endocrinology, Laguna Hill, California, United States
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
- Conditions
- Male Hypogonadism
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 182
- Registration Number
- NCT01699178
- Locations
- 🇺🇸
Providence Clinical Research, Burbank, California, United States
🇺🇸Alabama Clinical Therapeutics, Inc., Birmingham, Alabama, United States
🇺🇸Alabama Clinical Therapeutics, Calera, Alabama, United States
Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
- Conditions
- Male Hypogonadism
- Interventions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT01403116
- Locations
- 🇺🇸
Bruce R. Gilbert, MD, PhD, Great Neck, New York, United States
🇺🇸Providence Clinical Research, Burbank, California, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation
- Conditions
- Male Hypogonadism
- Interventions
- Drug: Oral testosterone undecanoate (containing 300 mg T)
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00924612
- Locations
- 🇺🇸
LABiomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇨🇦Anapharm, Inc., Quebec City, Quebec, Canada
Pharmacokinetic Study to Determine Time to Steady-state
- Conditions
- Primary HypogonadismMale HypogonadismSecondary Hypogonadism
- Interventions
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Clarus Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00911586
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, Birmingham, Alabama, United States